Financings in Brief: Focal, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Focal, Inc.: Surgical sealant developer goes public Dec. 12 via an initial offering of 2.5 mil. shares at $10 each, grossing $25 mil. Lexington, Massachusetts-based Focal plans to submit a premarket approval application to FDA by the end of 1998 for its FocalSeal surgical sealant product for sealing air leaks in lungs after surgery, and hopes to commence European sales in the near future ("The Gray Sheet" Oct. 6, In Brief). The technology also has potential applications in neurosurgery, cardiovascular and gastrointestinal surgery, the firm says. Proceeds from the offering will fund continued R&D, clinical trials, "expansion of manufacturing capabilities and sales and marketing activities and capital expenditures," the firm states. Underwriters Lehman Brothers, Piper Jaffray, and Pacific Growth Equities hold an overallotment option for 375,000 additional shares...
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.